By DEEKSHA HEGDE
I had an itch to attract parallels between the 2. The structural details saved lining up in methods I couldn’t dismiss, and by the top, I finished making an attempt.
Perform’s product is an app: you pay $365 a yr, go to a Quest Diagnostics location, get 160+ biomarkers examined twice a yr, and obtain clinician-written notes decoding your outcomes. The lab testing is absolutely outsourced. Perform is the layer on prime: panel design, member expertise, clinician notice technology, longitudinal monitoring.
Perform Well being raised $298 million at a $2.5 billion valuation in November 2025. At 25x income, the market clearly isn’t shopping for a lab reseller. It’s shopping for the info flywheel: longitudinal biomarker histories that compound in medical worth over time, aggregated throughout a whole lot of 1000’s of members right into a dataset that well being plans, pharma firms, and AI builders can’t construct every other means. A member with 4 years of information can’t swap to a less expensive competitor with out dropping the development. The unit economics work if the interpretation layer scales with out proportionally scaling headcount, which is what the Medical Intelligence Lab, their generative AI mannequin launched in November 2025, is constructed to do. Perform can also be constructing towards a B2B enterprise channel, positioning the product as a strategy to hold staff “wholesome, centered, and able to carry out.”
It satisfies a burning want for particular personas: the nervous effectively, the well being optimizers, the individuals who noticed their family members get identified a little bit too late, the individuals who aren’t ready for a analysis earlier than they begin paying consideration. These are individuals the remainder of the trade has principally left alone. I wrote earlier this yr, in a bit on Hinge Well beingconcerning the prevention paradox: the employer ROI mannequin is structurally blind to the member who advantages most from early intervention. Perform skips the employer ROI story solely, costs the member instantly, and doesn’t attempt to show a CFO case it will possibly’t make. But.
Take apoB, brief for apolipoprotein B, one among Perform’s most prominently marketed biomarkers, a greater predictor of cardiovascular danger than the LDL take a look at most annual physicals nonetheless depend on. The Swedish AMORIS cohort research adopted 137,000 individuals for a mean of 17.8 years and located that elevated apoB separates circumstances from controls roughly 20 years earlier than a serious cardiovascular occasion, with the hole sharpening over the last decade closest to the occasion. Catch it, act on it — statins, dietary modifications, nearer monitoring — and you might stop a coronary heart assault. That’s actual medical worth.
Now run the employer math. Median personal sector tenure in the US is 3.5 years. The employer funding the Perform membership will nearly definitely not be insuring this particular person when that cardiovascular occasion materializes. The prevented value accrues to whoever covers them in fifteen years. The CFO writing the examine at the moment captures none of it. What Perform is definitely promoting proper now to employers is a wellness perk. Higginbotham, an insurance coverage dealer, introduced a partnership in January 2026 providing Perform to staff at $334 as a substitute of $365. A $31 low cost. You don’t construct a $2.5 billion firm on a health club stipend.
What well being plans and pharma companions would really pay for doesn’t exist but: actuarial danger fashions and analysis datasets constructed on years of longitudinal biomarker information at scale. The D2C subscription is the info acquisition engine for that product. Every part is dependent upon the flywheel working lengthy sufficient to shut the hole.
That’s the place the 23andMe comparability clicked for me.
23andMe was a D2C well being information firm whose valuation rested on an information monetization thesis: pharma analysis partnerships, information licensing. Package gross sales alone couldn’t justify it. It wasn’t a HIPAA-covered entity, and it collected delicate well being information underneath a privateness coverage that reserved the appropriate to switch it in a sale or chapter. The buyer advertising, although, by no means stated any of this. 23andMe led with ancestry, which made it viral, emotionally sticky, and FDA-adjacent relatively than FDA-regulated. Well being stories have been the upsell. “Contributing to science” was how they framed information acquisition: altruism, not a transaction. The GSK partnership ($300 million for analysis entry to the genetic database) was disclosed within the phrases of service, for the individuals who learn the tremendous print. When the enterprise failed, the info was a sellable asset, and Regeneron grabbed it in a storage sale.
Perform is structurally comparable, with larger stakes on each dimension. D2C well being information firm, information monetization thesis: enterprise danger fashions, analysis partnerships, AI. Additionally not a HIPAA-covered entity. It doesn’t invoice insurance coverage and isn’t a lined healthcare supplier, which implies the authorized protections most members assume apply to their well being information don’t. The similar chapter switch loophole that caught 23andMe’s members would catch Perform’s too.
23andMe’s income mannequin was damaged from day one: purchase a package as soon as, finished. Perform has recurring subscriptions and actual switching prices. 23andMe additionally imploded making an attempt to turn into a therapeutics firm, a pivot that required capabilities solely overseas to what it had. Perform’s monetization path is not less than adjoining to what it already does.
However the regulatory publicity is equivalent, and that window is closing. The FTC up to date its Well being Breach Notification Rule in April 2024, explicitly extending it to well being apps and D2C platforms, and has already used it in opposition to GoodRx, Premom, and BetterHelp. HYPERthe Well being Info Privateness Reform Act launched in November 2025, would lengthen HIPAA-equivalent obligations to precisely the class of firm Perform is.
The info Perform holds makes this publicity worse. 23andMe held genetic predisposition information: probabilistic, future-oriented, a danger modifier. Perform’s biomarker information is present: thyroid perform, metabolic standing, hormonal profile, cardiovascular markers, up to date twice a yr. Extra actionable, extra temporally exact, extra instantly helpful to anybody making selections based mostly in your well being.
Which ends up in an issue Perform hasn’t absolutely named. Their D2C model runs on a selected promise: your information is yours, and we’re serving to you perceive it. That’s what acquired 200,000 members. 23andMe acquired its first hundreds of thousands the identical means, utilizing aspirational id advertising to seize information belongings, whereas the precise worth creation required a B2B transaction that the buyer advertising by no means ready the person for. Perform’s member base skews extra refined than 23andMe’s ever did — these are individuals who already imagine their information has medical worth. Perform’s advertising hasn’t constructed the narrative structure but to ask them right into a transaction they’re already in.
The playbook exists. Oura selected the NBA and UCSF as analysis companions. These are establishments that made members really feel like individuals in one thing elite and scientific. Whoop publishes findings utilizing mixture member information. In each circumstances, the identical underlying information transaction reads as an identity-enhancing contribution as a result of the framing was constructed into the model from the beginning, not buried within the phrases of service. Perform’s biomarker information is extra clinically delicate than wearable information like HRV and sleep phases, and its B2B thesis extra load-bearing, which implies the identical playbook wants extra rigor in execution. Companion choice is model work: the primary disclosed analysis partnerships will set the body for all the things. Publishing findings normalizes the info relationship whereas constructing the product validity case Perform wants earlier than well being plans will write a examine.
Perform is already executing on components of this playbook — the NBPA partnership in February 2026 brings biomarker testing to skilled athletes, and the model sign is actual. However a distribution deal isn’t a analysis relationship. What’s lacking is analysis partnerships structured to supply and publish findings, the sort that flip distribution into proof, and proof into retention.
There’s one other layer that neither Oura nor Whoop has constructed. Proactive information governance is what makes the contribution framing credible relatively than simply model copy. Perform presently describes itself as “HIPAA-aligned”, following key necessities of the Safety Rule voluntarily. That’s the hole in a single phrase. Safety practices with out authorized dedication don’t shut the chapter switch loophole, don’t fulfill IRB consent necessities for future pharma companions, and don’t give insurance coverage companions the peace of mind they should license a dataset with out importing regulatory publicity. Adopting HIPAA-equivalent information dealing with earlier than HIPRA passes and framing it as a product determination relatively than a compliance response protects the flywheel from being dismantled earlier than it matures.
Perform has a window to behave by itself phrases. 23andMe waited for regulators to write down the foundations and have become the cautionary story these guidelines have been named after. Perform might write the playbook as a substitute.
Deeksha Hegde is a bioengineer who writes about healthtech and digital well being positioning on Substack.
